Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu, Japan.
Br J Pharmacol. 2019 Oct;176(20):4002-4018. doi: 10.1111/bph.14804. Epub 2019 Sep 15.
Lurasidone is an atypical mood-stabilizing antipsychotic with a unique receptor-binding profile, including 5-HT receptor antagonism; however, the detailed effects of 5-HT receptor antagonism on various transmitter systems relevant to schizophrenia, particularly the thalamo-insular glutamatergic system and the underlying mechanisms, are yet to be clarified.
We examined the mechanisms underlying the clinical effects of lurasidone by measuring the release of l-glutamate, GABA, dopamine, and noradrenaline in the reticular thalamic nucleus (RTN), mediodorsal thalamic nucleus (MDTN) and insula of freely moving rats in response to systemic injection or local infusion of lurasidone or MK-801 using multiprobe microdialysis with ultra-HPLC.
Systemic MK-801 (0.5 mg·kg ) administration increased insular release of l-glutamate, dopamine, and noradrenaline but decreased GABA release. Systemic lurasidone (1 mg·kg ) administration also increased insular release of l-glutamate, dopamine, and noradrenaline but without affecting GABA. Local lurasidone administration into the insula (3 μM) did not affect MK-801-induced insular release of l-glutamate or catecholamine, whereas local lurasidone administration into the MDTN (1 μM) inhibited MK-801-induced insular release of l-glutamate and catecholamine, similar to the 5-HT receptor antagonist SB269970.
The present results indicate that MK-801-induced insular l-glutamate release is generated by activation of thalamo-insular glutamatergic transmission via MDTN GABAergic disinhibition resulting from NMDA receptor inhibition in the MDTN and RTN. Lurasidone inhibited this MK-801-evoked insular l-glutamate release through inhibition of excitatory 5-HT receptor in the MDTN. These effects on thalamo-insular glutamatergic transmission may contribute to the antipsychotic and mood-stabilizing actions of lurasidone.
鲁拉西酮是一种具有独特受体结合谱的非典型心境稳定剂,包括 5-HT 受体拮抗作用;然而,5-HT 受体拮抗作用对各种与精神分裂症相关的递质系统的详细影响,特别是丘脑-岛叶谷氨酸能系统及其潜在机制,仍有待阐明。
我们通过使用超高效液相色谱多探针微透析测量自由活动大鼠网状丘脑核(RTN)、中脑背侧丘脑核(MDTN)和脑岛中海马酸、GABA、多巴胺和去甲肾上腺素的释放,研究了鲁拉西酮临床作用的潜在机制。
系统给予 MK-801(0.5mg·kg )增加了脑岛中海马酸、多巴胺和去甲肾上腺素的释放,但降低了 GABA 的释放。系统给予鲁拉西酮(1mg·kg )也增加了脑岛中海马酸、多巴胺和去甲肾上腺素的释放,但不影响 GABA。局部给予鲁拉西酮(3μM)到脑岛不会影响 MK-801 诱导的脑岛中海马酸或儿茶酚胺的释放,而局部给予鲁拉西酮(1μM)到 MDTN 抑制了 MK-801 诱导的脑岛中海马酸和儿茶酚胺的释放,与 5-HT 受体拮抗剂 SB269970 相似。
本研究结果表明,MK-801 诱导的脑岛中海马酸释放是通过 MDTN 中 GABA 能抑制作用引起的丘脑-岛叶谷氨酸能传递的激活而产生的,这是由于 MDTN 和 RTN 中 NMDA 受体抑制。鲁拉西酮通过抑制 MDTN 中的兴奋性 5-HT 受体抑制了这种 MK-801 诱导的脑岛中海马酸释放。这些对丘脑-岛叶谷氨酸能传递的影响可能有助于鲁拉西酮的抗精神病和心境稳定作用。